AzTrials
AzTrials

MyopathyNCT06837467

Differential SERCA Expression in Laryngeal Muscles

A study testing Immunohistochemistry (IHC) in people with Myopathy, run by Sohag University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Immuno-localization of SERCA and MHC isoform (SERCA1, SERCA2, MHC I, and MHCII) expression and co-expression in the five ILMs were investigated in both young and aged rats with immunohistochemistry. Special concern has been placed to the denervation effect on ILMS. Read more about this study

Who is it for?
Ages 8 to 24 weeks, men only
Conditions the study is for
Myopathy
What is being tested?
Immunohistochemistry (IHC)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteEgypt
Study dates
25 Jan 2024to 1 Feb 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 to 24 weeks
  • Men only
  • No healthy volunteers
  • Child

Who may be able to join

  • 8-12 weeks of age, weighing 280-350 g (N=10) were used as young rats. In addition, 24-month-old rats (N=10) were employed as aged models.

Who cannot join

  • -

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Sohag University

    Sohag, 82524

Other trials in Egypt

About this study

Official title: Differential Expression of SERCA and Myosin Heavy Chain Isoforms in Rat Laryngeal Muscles

Immuno-localization of SERCA and MHC isoform (SERCA1, SERCA2, MHC I, and MHCII) expression and co-expression in the five ILMs were investigated in both young and aged rats with immunohistochemistry. Special concern has been placed to the denervation effect on ILMS.

Read the detailed description

Animals In this study, male adult Wistar rats (Shimizu Laboratory Supplies Co., Kyoto, Japan), 8-12 weeks of age, weighing 280-350 g (N=10) were used as young rats. In addition, 24-month-old rats (N=10) were employed as aged models.

Animal tissue preparation Animals were anesthetized with an intraperitoneal injection of sodium pentobarbital (dose 30-60 mg/kg) and were fixed with 4% paraformaldehyde following cardiac perfusion with 0.01 M phosphate-buffered saline (PBS). The larynges were excised immediately and immersed in the same fixative for approximately 12 hours at (4°C). Tissues were processed in paraffin and sectioned using a microtome (8-10 μm thickness).

The intrinsic laryngeal muscles studied were: 1) medial and lateral thyroarytenoid (MTA, LTA), (2) lateral cricoarytenoid (LCA), (3) Superior cricoarytenoid (SCA), (4) posterior cricoarytenoid (PCA), and (5) cricothyroid (CT).

Immunohistochemistry (IHC) The investigators faced unsuccessful fast fiber type identification on frozen sections then we shifted to paraffin sections. Deparaffinized sections were incubated with 3% H2O2 in PBS for 10 minutes followed by microwave treatment (5 minutes ×3 times at 500 Watt in citrate buffer, pH 6). Then, sections were incubated in a blocking solution (0.3 M glycine, 50 mM ammonium chloride, and 1% BSA in PBS) for 30 minutes before incubation in primary antibodies. Sections were incubated with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed, and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC, the same steps were done with a mixture of primary or secondary antibodies with the same dilutions.

Immunostained tissue sections were examined using a FV-1000 laser confocal microscope (Olympus, Tokyo, Japan). ImageJ 1.46 software was used to manually count and calculate the percentage of positive cells for each antibody.

Immunohistochemistry for denervated rat In 8-12 weeks, aged rats, the larynx was approached through a midline incision using a standard operating microscope under anesthesia with sodium pentobarbital. After identification of the right recurrent and superior laryngeal nerves, a 1 cm segment was removed from the right recurrent laryngeal nerve and both ends were ligated. The right superior laryngeal nerve was also divided. The denervated rat groups were sacrificed after 2, 4, 8, and 12 weeks. The larynx was collected and prepared for IHC using the same procedure described above (n = 5 in each group).

MHC subtypes using multi-color fiber typing:

At the beginning of our research, we tried the frozen section. After trials of several techniques to decrease autofluorescence and background noise, the investigators failed to have good staining. Then, the investigators discontinued MHC subtyping and shifted to paraffin-embedded blocks Statistical analysis The relative SERCA and MHC composition for each muscle was calculated. The available data for the positive cell percentage of each rat antibody were statistically analyzed using SPSS statistical software, version 16. Statistical comparisons were performed using the unpaired two-tailed Student's t-test and were considered significant at P < 0.05.

One-way analysis of variance (ANOVA) followed by Scheffe's post hoc test was performed to compare the MHC and SERCA composition for each muscle in denervation with the contralateral side and young with age. Values presented are means ± SD (standard deviation), with SD being across rats.

Conditions
Myopathy
Being tested
Immunohistochemistry (IHC)
Keywords
SERCA and MHC isoform
Medical subject headings
Muscular Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Immunohistochemistry (IHC)Diagnostic test

    We faced unsuccessful fast fiber type's identification on frozen sections then we shifted to paraffin sections. Deparaffinized sections were incubated with 3% H2O2 in PBS for 10 minutes followed by microwave treatment (5 minutes ×3 times at 500 Watt in citrate buffer, pH 6). Then, sections were incubated in blocking solution (0.3 M glycine, 50 mM ammonium chloride, and 1% BSA in PBS) for 30 minutes before incubation in primary antibodies. Sections were incubated with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed, and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC, the same steps were done as before with mixture of primary or secondary antibodies with same dilutions.

Study groups in NCT06837467
Study groupRoleWhat they receive
Young ratExperimentalmale adult Wistar rats (Shimizu Laboratory Supplies Co., Kyoto, Japan), 8-12 weeks of age, weighing 280-350 g (N=10) were used as young rats Immunohistochemistry (IHC) with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC, the same steps were done as before with mixture of primary or secondary antibodies with same dilutions.
Receives: Diagnostic Test: Immunohistochemistry (IHC)
old ratsExperimental24-month-old rats (N=10) were employed as aged models. Immunohistochemistry (IHC) with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed, and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC, the same steps were done as before with mixture of primary or secondary antibodies with same dilutions.
Receives: Diagnostic Test: Immunohistochemistry (IHC)
Denervated ratsActive comparatorIn 8-12 weeks, aged rats, the larynx was approached through a midline incision using a standard operating microscope under anesthesia with sodium pentobarbital. After identification of the right recurrent and superior laryngeal nerves, a 1 cm segment was removed from the right recurrent laryngeal nerve and both ends were ligated. The right superior laryngeal nerve was also divided. The denervated rat groups were sacrificed after 2, 4, 8, and 12 weeks. The larynx was collected and prepared for IHC using the same procedure described above (n = 5 in each group). Immunohistochemistry (IHC) with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed, and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC.
Receives: Diagnostic Test: Immunohistochemistry (IHC)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Immuno-localization of SERCA and MHC isoform

    Immuno-localization of SERCA and MHC isoform (SERCA1, SERCA2, MHC I, and MHCII) expression and co-expression in the five ILMs

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Feb 2025
  2. Study start25 Jan 2024
  3. Primary completion25 Jan 2025
  4. Study completion1 Feb 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Model description
In this study, male adult Wistar rats (Shimizu Laboratory Supplies Co., Kyoto, Japan), 8-12 weeks of age, weighing 280-350 g (N=10) were used as young rats. In addition, 24-month-old rats (N=10) were employed as aged models. In 8-12 weeks, aged rats, the larynx was approached through a midline incision using a standard operating microscope under anesthesia with sodium pentobarbital. After identification of the right recurrent and superior laryngeal nerves, a 1 cm segment was removed from the right recurrent laryngeal nerve and both ends were ligated. The right superior laryngeal nerve was also divided. The denervated rat groups were sacrificed after 2, 4, 8, and 12 weeks. The larynx was collected and prepared for IHC using the same procedure described above (n = 5 in each group).
Masking
Single blind
Who is masked
Participant
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06837467
Sponsor's protocol ID
sohag-5-24-2023-01
Status last verified
Feb 2025
First submitted
7 Feb 2025
Last updated
20 Feb 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Mao VH, Abaza M, Spiegel JR, Mandel S, Hawkshaw M, Heuer RJ, Sataloff RT. Laryngeal myasthenia gravis: report of 40 cases. J Voice. 2001 Mar;15(1):122-30. doi: 10.1016/S0892-1997(01)00012-1.

    PubMed 12269627
  • Marques MJ, Ferretti R, Vomero VU, Minatel E, Neto HS. Intrinsic laryngeal muscles are spared from myonecrosis in the mdx mouse model of Duchenne muscular dystrophy. Muscle Nerve. 2007 Mar;35(3):349-53. doi: 10.1002/mus.20697.

    PubMed 17143878

Questions about this trial

What is this clinical trial studying?

A study testing Immunohistochemistry (IHC) in people with Myopathy, run by Sohag University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Immuno-localization of SERCA and MHC isoform (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06837467, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in